SEC Form 4 · accession 0001193805-15-001979
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam S Grossman
Officer — President & CEO · Director
Period of report
Dec 1, 2015
Accepted (ET)
Dec 3, 2015 · 7:59 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value per shareF1,F2,F3,F4 | Dec 1, 2015 | P | 1,800 | $9.1737 | A | 634,518 | I | Please see footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.1682 to $9.1832 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on December 1, 2015.
- F2580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- F347,800 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- F4These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.